New hope for tough lymphoma: phase 3 trial pits SHR2554 against standard drug
NCT ID NCT06122389
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial compares a new drug called SHR2554 to an existing drug, chidamide, in 130 people with a rare type of lymphoma (PTCL) that has come back or not responded to at least one prior treatment. The main goal is to see if SHR2554 can delay cancer growth better than chidamide. Participants will receive either SHR2554 or chidamide, plus a dummy version of the other drug, so neither they nor their doctors know which they are getting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR2554 (a drug being tested) and chidamide (a standard drug)
What this could lead to
If SHR2554 works better than chidamide, it could offer a new treatment option for people with PTCL that has come back or not responded to prior therapy.
What could go wrong
This is a phase 3 trial, but it is still experimental. The new drug may not prove superior to the existing drug, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••